Dyno Therapeutics
The AI Product Manager will lead the development of Dyno’s external AI platforms for biological design, collaborating with scientists, engineers, and wet‑lab teams to turn complex biological problems into production‑ready systems. The role focuses on building AI‑driven workflows, APIs, and tools that integrate modeling, data, and experimental feedback to accelerate therapeutic development.
Headquarters
Watertown, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Dyno is a biotech company focused on building high-performance genetic technologies to transform patient lives. The company develops advanced gene‑delivery platforms and a platform-driven translational approach to turn engineered genetic tools into therapies. Dyno emphasizes collaboration and partnerships with biopharma to advance development and bring genetic medicines to patients.
Dyno Therapeutics Unveils Best-in-Class Dyno-bn8 AAV Vector for Muscle Gene Therapies, Achieving Therapeutic Delivery With Improved Safety Potential
Nov 11, 2025
Dyno Therapeutics and Trisk Bio partner for strategic manufacture
Nov 12, 2025
Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio
Jan 12, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Dyno Therapeutics.
55% above the average for this role
Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner
Nov 11, 2025